For this phase @/@ cluster-randomised , double-blind trial , undertaken between Feb @ , @ , and Dec @ , @ , in municipal health-care centres and the Tampere University Vaccine Research Centre ( Finland ) , we randomly assigned ( @:@:@:@ ) @ clusters into PHiD-CV@ three plus one , PHiD-CV@ two plus one , control three plus one , control two plus one groups ( @:@:@:@ clusters ) to give PHiD-CV@ in either three plus one or two plus one schedule ( if enrolled before @ months of age ; infant schedules ) , two plus one ( if enrolled between @ and @ months ; catch-up schedules ) , and two doses at least @ months apart ( if enrolled between @ and @ months ; catch-up schedules ) .